Research and Development

Novartis will make use of a technology developed by Synthetic Genomics Vaccines, a new company set up by genomics pioneer …

AstraZeneca is due to begin enrolling patients into a new study of its oral antiplatelet Brilique (ticagrelor) before the end …

Merck & Co has signed a drug development agreement with anti-infective pharma firm BioRelix to development a new class of …

Austrian biotech Intercell Biomedical has appointed Eric Frings as site director of its Livingston, Scotland operations.He joins the firm from …

Novartis will incur a charge of nearly $600 million after it halted development of investigational drugs for hepatitis C and …

Competition in the field of COPD and asthma is hotting up, with new data for several key treatments recently unveiled. …

The eCTD was of course developed by the ICH (International Conference on Harmonisation) Expert Working Group to make it easier, …

GlaxoSmithKline has taken a stake in a newly-launched biotech company in return for handing it two clinical compounds. The pharma …

US global specialty pharmaceutical company Hospira has appointed Svend Andersen to lead its operations in Europe with effect from 1 …

The European Union (EU) Module 1 specification works in parallel with the ICH eCTD Specification. It was first introduced in …

Sanofi-Aventis’ courtship dance around Genzyme has turned more aggressive with an offer – made over the heads of Genzyme’s board …

Poor phase III results have forced GlaxoSmithKline to halt development of its Simplirix vaccine for women with genital herpes. The …

Recent speculation surrounding current diabetes drugs and their long term effect on cardiovascular health has heads spinning in the pharmaceutical …

AstraZeneca and Bristol Myers Squibb’s potential first-in-class diabetes drug dapagliflozin has shown strong results in a late stage trial. It …

The FDA has clarified its rules on what safety information must be reported during clinical trials of investigational drugs and …